Telomir Pharmaceuticals (TELO) Competitors $4.23 -0.12 (-2.76%) Closing price 03/10/2025 04:00 PM EasternExtended Trading$4.22 -0.02 (-0.35%) As of 03/10/2025 05:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends TELO vs. PGEN, MAZE, GHRS, CGEM, AUTL, ABVX, DNA, CMRX, KROS, and SAGEShould you be buying Telomir Pharmaceuticals stock or one of its competitors? The main competitors of Telomir Pharmaceuticals include Precigen (PGEN), Maze Therapeutics (MAZE), GH Research (GHRS), Cullinan Therapeutics (CGEM), Autolus Therapeutics (AUTL), ABIVAX Société Anonyme (ABVX), Ginkgo Bioworks (DNA), Chimerix (CMRX), Keros Therapeutics (KROS), and Sage Therapeutics (SAGE). These companies are all part of the "pharmaceutical products" industry. Telomir Pharmaceuticals vs. Precigen Maze Therapeutics GH Research Cullinan Therapeutics Autolus Therapeutics ABIVAX Société Anonyme Ginkgo Bioworks Chimerix Keros Therapeutics Sage Therapeutics Precigen (NASDAQ:PGEN) and Telomir Pharmaceuticals (NASDAQ:TELO) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, risk, profitability, dividends, earnings, media sentiment and community ranking. Which has preferable valuation & earnings, PGEN or TELO? Telomir Pharmaceuticals has lower revenue, but higher earnings than Precigen. Telomir Pharmaceuticals is trading at a lower price-to-earnings ratio than Precigen, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPrecigen$3.96M130.80-$95.90M-$0.55-3.22Telomir PharmaceuticalsN/AN/A-$16.53M-$0.58-7.29 Does the media prefer PGEN or TELO? In the previous week, Telomir Pharmaceuticals had 1 more articles in the media than Precigen. MarketBeat recorded 1 mentions for Telomir Pharmaceuticals and 0 mentions for Precigen. Telomir Pharmaceuticals' average media sentiment score of 1.95 beat Precigen's score of 0.00 indicating that Telomir Pharmaceuticals is being referred to more favorably in the news media. Company Overall Sentiment Precigen Neutral Telomir Pharmaceuticals Very Positive Does the MarketBeat Community favor PGEN or TELO? Precigen received 434 more outperform votes than Telomir Pharmaceuticals when rated by MarketBeat users. However, 100.00% of users gave Telomir Pharmaceuticals an outperform vote while only 67.39% of users gave Precigen an outperform vote. CompanyUnderperformOutperformPrecigenOutperform Votes43667.39% Underperform Votes21132.61% Telomir PharmaceuticalsOutperform Votes2100.00% Underperform VotesNo Votes Is PGEN or TELO more profitable? Telomir Pharmaceuticals has a net margin of 0.00% compared to Precigen's net margin of -3,521.68%. Precigen's return on equity of -123.06% beat Telomir Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Precigen-3,521.68% -123.06% -87.33% Telomir Pharmaceuticals N/A -1,170.58%-832.67% Do insiders & institutionals have more ownership in PGEN or TELO? 33.5% of Precigen shares are held by institutional investors. 44.9% of Precigen shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Do analysts rate PGEN or TELO? Precigen presently has a consensus price target of $7.00, suggesting a potential upside of 295.48%. Telomir Pharmaceuticals has a consensus price target of $15.00, suggesting a potential upside of 254.61%. Given Precigen's higher probable upside, equities analysts clearly believe Precigen is more favorable than Telomir Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Precigen 1 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.60Telomir Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.50 SummaryPrecigen beats Telomir Pharmaceuticals on 10 of the 17 factors compared between the two stocks. Remove Ads Get Telomir Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for TELO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TELO vs. The Competition Export to ExcelMetricTelomir PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$125.90M$7.11B$5.72B$8.00BDividend YieldN/A2.72%4.89%4.03%P/E Ratio-7.296.3024.9218.89Price / SalesN/A219.97401.45115.03Price / CashN/A65.6738.0534.62Price / Book211.506.387.274.15Net Income-$16.53M$140.25M$3.19B$246.75M7 Day Performance4.44%0.02%-0.20%-1.59%1 Month Performance-3.20%-7.02%-5.98%-8.59%1 Year Performance-38.43%-10.95%11.72%-0.53% Telomir Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TELOTelomir Pharmaceuticals2.5747 of 5 stars$4.23-2.8%$15.00+254.6%-50.0%$125.90MN/A-7.291Positive NewsGap DownPGENPrecigen3.2266 of 5 stars$1.67-3.5%$7.00+319.2%+1.1%$489.09M$3.96M-3.04190MAZEMaze TherapeuticsN/A$11.04-9.7%$25.67+132.5%N/A$483.30M$167.50M0.00121Quiet Period ExpirationGHRSGH Research1.9719 of 5 stars$9.21-9.1%$30.60+232.2%+38.1%$479.18MN/A-11.6610Analyst ForecastAnalyst RevisionGap DownHigh Trading VolumeCGEMCullinan Therapeutics2.0438 of 5 stars$8.00-5.8%$32.50+306.3%-51.5%$465.82MN/A-2.8230AUTLAutolus Therapeutics2.8874 of 5 stars$1.75+1.2%$10.40+494.3%-66.0%$465.66M$10.09M-1.45330Upcoming EarningsABVXABIVAX Société Anonyme1.6676 of 5 stars$7.33-4.6%$38.67+427.5%-54.4%$464.47MN/A0.0061DNAGinkgo Bioworks0.8634 of 5 stars$8.04-2.4%$4.58-43.1%N/A$462.13M$227.04M-0.611,218Gap DownCMRXChimerix2.663 of 5 stars$5.04-4.0%$9.00+78.6%+571.4%$453.28M$159,000.00-5.3690High Trading VolumeKROSKeros Therapeutics3.7308 of 5 stars$11.10+0.2%$42.33+281.4%-84.5%$449.63M$3.55M-2.13100Positive NewsSAGESage Therapeutics3.7005 of 5 stars$7.20-1.4%$8.88+23.3%-67.1%$448.81M$41.24M-1.09690 Remove Ads Related Companies and Tools Related Companies Precigen Alternatives Maze Therapeutics Alternatives GH Research Alternatives Cullinan Therapeutics Alternatives Autolus Therapeutics Alternatives ABIVAX Société Anonyme Alternatives Ginkgo Bioworks Alternatives Chimerix Alternatives Keros Therapeutics Alternatives Sage Therapeutics Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:TELO) was last updated on 3/11/2025 by MarketBeat.com Staff From Our PartnersElon Musk Wants to Audit Fort Knox—What It Means for Your RetirementYou can take advantage of the coming tariff-fueled gold melt-up right inside your IRA or 401(k) – 100% TAX-FRE...Colonial Metals | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredTrump doesn’t give a damnPorter Stansberry: “I met with Trump’s biggest backers… they’re scooping up these 10 stocks” I recently met...Porter & Company | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredAlert: DOGE goes liveElon will most likely be at the helm of it all. And just days from now, could bring about the biggest econo...Altimetry | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Telomir Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Telomir Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free TELO Stock Alerts